AVEO’s admittance of AV-299 Usher in 2 hard times in support of lung cancer triggers $750,000 milestone payment to XOMA
XOMA Ltd. (Nasdaq:XOMA), a concert-master in the ascertaining and maturation of salubrious antibodies, announced counterfoil of a $750,000 milestone payment call of its collaboration with AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO). The milestone payment resulted from AVEO’s late admission of a Wind up 2 clinical pain in the neck to quantify its AV-299 antibody for the treatment of the treatment of non-small apartment lung cancer. AV-299 is a humanized antibody to hepatocyte nurturing aspect (HGF).
XOMA has signed more than 60 entitle and collaboration agreements with pharmaceutical and biotechnology companies affiliated to its patented technologies and its antibody origination, advance and optimization adroitness. These agreements pretence a million of budding merchandise candidates in heterogeneous stages of clinical and preclinical expansion concerning which XOMA may be entitled to unborn milestone and peerage payments.
Source XOMA Ltd.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
